Trial Profile
Comparison of Sugammadex Dosages to Reverse the Effect of Rocuronium for Continuous Intraoperative Neuromonitoring in Thyroid Surgery
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Oct 2021
Price :
$35
*
At a glance
- Drugs Sugammadex (Primary)
- Indications Neuromuscular blockade
- Focus Therapeutic Use
- 01 Sep 2021 Primary endpoint (Quality of signal of neuromonitoring) has not been met as per results published in the Laryngoscope
- 01 Sep 2021 Results published in the Laryngoscope
- 08 Jun 2020 Status changed from not yet recruiting to completed.